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CXCL9 expression and purification: Identifying further
structural and functional relationships with ligands

Abstract
Chemokines are proteins that induce tissue
extravasation, promote differentiation, and induce
chemotaxis. Because of these properties, the chemokine’s
role in antitumor immune response is of great interest to
researchers. The CXCL9,10,11/CXCR3 axis is specific in
that it regulates immune cell migration, differentiation, and
activation, leading to tumor suppression. CXCL9 mainly
mediates lymphatic infiltration to the focal sites and
suppresses tumor growth. In this research, we expressed
the novel CXCL9 protein within competent BL21 cells.
Two variations of a pET22b plasmid were used, one with
PelB (to cleave initial methionine on protein sequence) and
one without. It was found that after induction, CXCL9 was
expressed without the PelB leader sequence. From here we
purified the CXCL9 protein and deduced that the overall
expression of the protein was more than favorable. After
isolating and concentrating the protein, a final
concentration of 92 mg/ml was determined. With the
purified protein, X-ray crystallographic studies will be used
to determine the 3-D structure of the protein. This interface
is important because it will impact the interaction with the
receptor; therefore, altering the CXCL9/CXCR3 axis.
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Introduction
Chemokines are small proteins, 8-15kD, which interact with G protein-coupled receptors in order to induce chemotaxis, tissue extravasation,
and promote differentiation [1]. The CXCL9, 10, 11/CXCR3 axis is important because it regulates the differentiation of naive T cells to T
helper 1 cells and leads to the migration of immune cells to specific tissues [5]. Due to these properties, the role of this specific axis in antitumor immune response is of great interest. The CXCL9, 10, 11/CXCR3 axis activates the paracrine axis, and inhibits the autocrine axis which
makes it a favorable target for drug development [5]. It has been shown that agents who change the paracrine CXCL9,10,11 expression, and
neutralize CXCR3 expression on cancer cells have shown anti-tumor activity in certain models [5]. Research has shown that plasmid borne
CXCL9 plus cisplatin changed colon and lung cancer reduction and cytotoxic lymphocyte activation [7]. Additionally, intra- tumoral CXCL9
and interleukin 2 in renal cell carcinoma tumor model ended up reducing tumor growth and angiogenesis [3]. CXCL12, a similar small protein
ligand, has been found to bind to heparin, and work with glycosaminoglycans to sequester the ligand to CXCR4 [2]. Identifying certain small
molecules that bind the CXCL9 will be beneficial because the small molecules can alter the function of the ligand and alter the
CXCL9/CXCR3 interaction and function, or will help describe how the ligand is sequestered and presented to the receptor.

The overall goal of the research is to purify CXCL9 and then use X-ray crystallography in order
to determine the protein's structure, and possible structural relationships with ligands

Results
Methodology
A transformation of three pET22b plasmids into
competent Bl21(DE3) cells was performed. The three
plasmids were wild type CXCL9, control, and CXCL9 with
PelB following Agilent Technologies Bl21(DE3)
competent cells protocol. An SDS-Page gel was run in
order to determine if PelB was effective.
An LB+ ampicillin 15 mL culture from a fresh Bl21
colony transformed with pET22b was set in a shaker
incubator overnight at 37*C. A subculture of 1:100 into LB
liquid was created and placed in shaker incubator for 2
hours at 37*C. The culture was induced with 1.5mL 1M
IPTG for 4 hours in a shaker incubator at 37*C. The cells
were harvested and spun down at 8krpm. The pellets were
then re-suspended in 30 mL 1XpBS+1%TX100+1/5Protease tablet. The re-suspended cells were
French Pressed twice. The cells were spun down again at
16 krpm for 25 minutes. Each pellet was re-suspended in
30 mL wash buffer and spun down again under the same
conditions, this was repeated twice. The pellets were resuspended in 6M Guanadine HCl to release the protein into
the supernatant. An SDS page gel was ran for samples from
the French press to the last wash. The supernatant was
diluted 1:100 into refolding buffer and added dropwise,
constantly stirring overnight at 4*C.
Once the protein of interest was isolated, it underwent
purification procedures. The protein solution was run
through an FPLC machine, the fractions were collected,
and an SDS-page gel was ran to determine suitable
fractions to pool. Next, the pooled fractions were run
through an HPLC machine, and only the distinct peak
containing the protein of interest was collected. The
purified protein solution was condensed and then
lyophilized overnight. The final purified product was resuspended in 500uL of ddH2O, and an SDS-Page gel was
ran of oxidized and reduced samples of CXCL9 to ensure
the right protein was purified.
Crystallization protocols were followed. 12mg/mL of
protein concentration was used, and then 88mg/mg of
protein into pre-made wells from various distributors to
maximize the possibility of crystallization using and NT8
Formulatrix Drop Setter.
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Figure 1: SDS-Page gel of
induced and uninduced samples
of WT and PelB CXCL9. (A)
Induced samples 1-6, induced
PelB samples 1-3. CXCL9 is
expressed in the induced samples
by a characteristic dark band (red
outline) from the WT plasmids.
The induced PelB 1-3 samples
show no clear expression of the
CXCL9 protein. (B) Induced PelB
samples 4-6 show no clear
expression of CXCL9. Uninduced
samples were ran as a reference.
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Figure 2: SDS-Page of final purified CXCL9 product, batch 1. The
final concentration of 2 purification batches was determined to be
88mg/mL and 56mg/mL. A serial dilution was performed on the
concentrated product, starting with a 1:50 dilution of protein to ddH2O,
two times. The left side of the gel shows reduced CXCL9 treated with
DTT. The reduced CXCL9 sample is shown to have traveled farther
down the gel, which is expected as the disulfide bonds within the
chemokine break. The right side of the gel shows the oxidized version of
CXCL9. The oxidized chemokine should travel less distance through the
gel when compared to the reduced version, as seen by the spacers under
the protein band on the right. The density within each band series
decreases as the dilution ratio increases.
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Discussion and Implications
A concentration of 88mg/ml was determined for the first
batch of CXCL9, and 56mg/ml for the second. These
concentrations reflect a good expression of the CXCL9
protein. The proper conditions for CXCL9 to be knocked
out of solution were tested. 12mg/mL was tested at first,
this proved to be a weak concentration as no proteins
crystallized. Even at an extremely high concentration of
88mg/mL, only three well out of 96 wells showed some
sort of crystals. However, these crystals could also be
inorganic salt precipitates. Since the protein is unable to be
knocked out of solution, it could be too stable. The protein
could also not be folded correctly and in solution like a big
noodle; therefore, not allowing crystallization to happen. I
would have liked to have a crystal structure by now, but
due to the current climate that was not able to happen.
Currently, I am working figuring out how to mutate the
protein to decrease stability, if the protein is too stable.
Furthermore, A2 and B22 virial coefficients might be
helpful in terms of the fact that they can be manipulated for
crystallography. A virial coefficient can be manipulated to
provide correction to the ideal gas law and are
characteristic of the interaction potential between particles
and depend on the temperature [6]. This coefficient may be
useful to manipulate within the well system in order to
achieve proper crystallization.
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Figure 3: Three X-Ray Crystallography Hampton HT plates
from 0 to 19 days with 0.4uL of an 88mg/mL CXCL9
concentration and 150uL well volume. Cells B1, C9 and F2
were determined to have some sort of crystalline structure. (B1)
0.2M Na3 Cit, 0.1M Tris 8.5 pH, 30 %v/v PEG 400. (C9) 4M Na
form. (F2) 0.2M K Na Tart, 0.1M Na3 Cit 5.6 pH, 2M
(NH4)2SO4.
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